Gujarat Magazine

Pulmonary Arterial Hypertension (PAH) Therapeutic Assessment, Emerging Therapies, Clinical and Non-Clinical Studies, Key Companies, Treatment Algorithm, and Pipeline Analysis

 Breaking News
  • No posts were found

Pulmonary Arterial Hypertension (PAH) Therapeutic Assessment, Emerging Therapies, Clinical and Non-Clinical Studies, Key Companies, Treatment Algorithm, and Pipeline Analysis

July 20
21:28 2021
Pulmonary Arterial Hypertension (PAH) Therapeutic Assessment, Emerging Therapies, Clinical and Non-Clinical Studies, Key Companies, Treatment Algorithm, and Pipeline Analysis

Delveinsight Business Research LLP

“Pulmonary Arterial Hypertension (PAH) Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Pulmonary Arterial Hypertension (PAH) Market.

The Pulmonary Arterial Hypertension (PAH) Pipeline report embraces in-depth commercial and clinical assessment of the Pulmonary Arterial Hypertension (PAH) pipeline products from the pre-clinical developmental phase to the marketed phase. 

The report covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pulmonary Arterial Hypertension (PAH) collaborations, mergers, acquisition, funding, designations, and other product-related details.

Get FREE sample copy at:

Pulmonary Arterial Hypertension (PAH) Pipeline Analysis

The market size of Pulmonary Arterial Hypertension (PAH) is anticipated to increase during the study period owing to the increasing incident population of PAH patients in the 7MM. Extensive research and development activities of pharmaceutical companies, along with the expected launch of approved therapies will also fuel the growth of the market.

Key Companies in the Pulmonary Arterial Hypertension (PAH) Market:

  • United Therapeutics Corp.

  • Arena Pharmaceuticals

  • Altavant Sciences

  • Acceleron Pharma

  • Reata Pharmaceuticals

  • Liquidia Technologies

  • PhaseBio Pharmaceuticals

  • Complexa

And many others.

Pulmonary Arterial Hypertension (PAH) Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Pulmonary Arterial Hypertension (PAH) with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late stage of development for the Pulmonary Arterial Hypertension (PAH) Treatment.

  • Pulmonary Arterial Hypertension (PAH) key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Pulmonary Arterial Hypertension (PAH) Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pulmonary Arterial Hypertension (PAH) market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Pulmonary Arterial Hypertension (PAH) Therapies covered in the report includes:

  • CXA-10

  • Aurora-GT

  • Ralinepag

  • RVT-1201

  • Sotatercept 

  • PB1046 Injection

  • Bardoxolone methyl 

  • Inhaled dry powder treprostinil 

And many more.

Request for Sample @ Pulmonary Arterial Hypertension (PAH) Novel Therapies And Emerging Technologies

Report Highlights

  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Pulmonary Arterial Hypertension (PAH).    

  • In the coming years, the Pulmonary Arterial Hypertension (PAH) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. 

  • The companies and academics are working to assess challenges and seek opportunities that could influence Pulmonary Arterial Hypertension (PAH) Research & Development. The therapies under development are focused on novel approaches to treat/improve the disease condition.

  • A detailed portfolio of major pharma players who are involved in fueling the Pulmonary Arterial Hypertension (PAH) treatment market. Several potential therapies for Pulmonary Arterial Hypertension (PAH) are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Pulmonary Arterial Hypertension (PAH) market size in the coming years.  

  • Our in-depth analysis of the Pulmonary Arterial Hypertension (PAH) pipeline assets (in early-stage, mid-stage, and late stage of development) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities. 

Table of Content

1. Report Introduction

2. Pulmonary Arterial Hypertension (PAH) 

3. Pulmonary Arterial Hypertension (PAH) Current Treatment Patterns

4. Pulmonary Arterial Hypertension (PAH) – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Pulmonary Arterial Hypertension (PAH) Late Stage Products (Phase-III)

7. Pulmonary Arterial Hypertension (PAH) Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Pulmonary Arterial Hypertension (PAH) Discontinued Products

13. Pulmonary Arterial Hypertension (PAH) Product Profiles

14. Pulmonary Arterial Hypertension (PAH) Key Companies

15. Pulmonary Arterial Hypertension (PAH) Key Products

16. Dormant and Discontinued Products

17. Pulmonary Arterial Hypertension (PAH) Unmet Needs

18. Pulmonary Arterial Hypertension (PAH) Future Perspectives

19. Pulmonary Arterial Hypertension (PAH) Analyst Review  

20. Appendix

21. Report Methodology

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at:

Latest Reports By DelveInsight

Pulmonary Arterial Hypertension (PAH) Market Insight

DelveInsight’s “Pulmonary Arterial Hypertension (PAH) Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Pulmonary Arterial Hypertension (PAH) market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

Emphysema Market Insight

DelveInsight’ s “Emphysema Market Insights, Epidemiology and Market Forecast – 2030” report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology and the Emphysema market size, share, trends, and forecast for the seven major markets (i.e. the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States